COREVALVE TO COMMENCE REVALVING SYSTEM CLINICAL TRIAL

CoreValve has received approval from the German government - Bezirksregierung Koln, state of Nordrhein-Westfalen, Cologne -- to immediately commence a clinical trial of its proprietary ReValving System to nonsurgically replace diseased aortic heart valves in 10 patients who are contraindicated for open-heart surgery. Previously, CoreValve received "local" IRB approval from The Heart Center, Seigburg, Germany, where the clinical trial will take place.

Business Wire

(http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050103005156&newsLang=en)